 The use of non-selected donor lymphocyte infusions DLIs to help early immune recovery and induce antitumor response following nonmyeloablative allogeneic stem cell transplantation ASCT is also complicated by the risk of acute graft versus host disease aGVHD with 30-40 of patients experiencing grade III-IV aGVHD. Data suggests that the use of natural killer NK cells instead of nonselected DLIs in this setting may mediate a graft versus tumor GVT effect independently of aGVHD. 